ENTPD1 and cancer: The exploration of autologous cell therapy has also advanced, particularly with PD-1+CD39+ selected TILs, which demonstrate multifunctional superiority through increased cytokine secretion, multi-cancer reactivity, and potent autologous tumor cytotoxicity [268].